JP2006508981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508981A5 JP2006508981A5 JP2004553729A JP2004553729A JP2006508981A5 JP 2006508981 A5 JP2006508981 A5 JP 2006508981A5 JP 2004553729 A JP2004553729 A JP 2004553729A JP 2004553729 A JP2004553729 A JP 2004553729A JP 2006508981 A5 JP2006508981 A5 JP 2006508981A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- therapeutic agent
- agent according
- alkyl
- cancer therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940124597 therapeutic agent Drugs 0.000 claims 20
- 239000012830 cancer therapeutic Substances 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 239000002246 antineoplastic agent Substances 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 229940127089 cytotoxic agent Drugs 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 229960002949 fluorouracil Drugs 0.000 claims 6
- -1 hydroxy, amino, monosubstituted amino Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 4
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 4
- 229960004562 carboplatin Drugs 0.000 claims 4
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 4
- 235000008191 folinic acid Nutrition 0.000 claims 4
- 239000011672 folinic acid Substances 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 229960001691 leucovorin Drugs 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
- 229930012538 Paclitaxel Natural products 0.000 claims 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 3
- 229960004316 cisplatin Drugs 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 3
- 229960005277 gemcitabine Drugs 0.000 claims 3
- 229960004768 irinotecan Drugs 0.000 claims 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229960001592 paclitaxel Drugs 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 2
- RBHBOUYXUXWCNJ-UHFFFAOYSA-N 5-[(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxylic acid Chemical compound OC(=O)C1=C(C)NC(C=C2C3=CC(F)=CC=C3NC2=O)=C1C RBHBOUYXUXWCNJ-UHFFFAOYSA-N 0.000 claims 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 2
- 102000014654 Aromatase Human genes 0.000 claims 2
- 108010078554 Aromatase Proteins 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims 2
- 102000029749 Microtubule Human genes 0.000 claims 2
- 108091022875 Microtubule Proteins 0.000 claims 2
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 229940127395 Ribonucleotide Reductase Inhibitors Drugs 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 229940123237 Taxane Drugs 0.000 claims 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 2
- 229940122803 Vinca alkaloid Drugs 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 229960002756 azacitidine Drugs 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 229960004117 capecitabine Drugs 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 229960005243 carmustine Drugs 0.000 claims 2
- 229960005395 cetuximab Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 2
- 229960000975 daunorubicin Drugs 0.000 claims 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960001904 epirubicin Drugs 0.000 claims 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
- 229960005420 etoposide Drugs 0.000 claims 2
- 229960000255 exemestane Drugs 0.000 claims 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims 2
- 229960000390 fludarabine Drugs 0.000 claims 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- 229960002584 gefitinib Drugs 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 229960001330 hydroxycarbamide Drugs 0.000 claims 2
- 229960000908 idarubicin Drugs 0.000 claims 2
- 229960001101 ifosfamide Drugs 0.000 claims 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- 229960002411 imatinib Drugs 0.000 claims 2
- 230000000937 inactivator Effects 0.000 claims 2
- 230000002427 irreversible effect Effects 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 229960002247 lomustine Drugs 0.000 claims 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 2
- 229960001428 mercaptopurine Drugs 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 210000004688 microtubule Anatomy 0.000 claims 2
- 229960004857 mitomycin Drugs 0.000 claims 2
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 2
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims 2
- 229960002340 pentostatin Drugs 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 239000000649 purine antagonist Substances 0.000 claims 2
- 239000003790 pyrimidine antagonist Substances 0.000 claims 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 2
- 229960004964 temozolomide Drugs 0.000 claims 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 2
- 229960001278 teniposide Drugs 0.000 claims 2
- 229960001196 thiotepa Drugs 0.000 claims 2
- 239000003734 thymidylate synthase inhibitor Substances 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000009657 thyroid sarcoma Diseases 0.000 claims 2
- 229960003087 tioguanine Drugs 0.000 claims 2
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 2
- 229960003048 vinblastine Drugs 0.000 claims 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 2
- 229960004528 vincristine Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
- 229960004355 vindesine Drugs 0.000 claims 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims 2
- GIARQKRMPGZBGK-UHFFFAOYSA-N 5-[(5-chloro-2-oxo-1h-indol-3-ylidene)methyl]-n-(2-hydroxy-3-morpholin-4-ylpropyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound CC=1NC(C=C2C3=CC(Cl)=CC=C3NC2=O)=C(C)C=1C(=O)NCC(O)CN1CCOCC1 GIARQKRMPGZBGK-UHFFFAOYSA-N 0.000 claims 1
- CTNPALGJUAXMMC-UHFFFAOYSA-N 5-[(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-n-(2-hydroxy-3-morpholin-4-ylpropyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound CC=1NC(C=C2C3=CC(F)=CC=C3NC2=O)=C(C)C=1C(=O)NCC(O)CN1CCOCC1 CTNPALGJUAXMMC-UHFFFAOYSA-N 0.000 claims 1
- CTNPALGJUAXMMC-MRXNPFEDSA-N 5-[(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-n-[(2r)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound C([C@H](O)CNC(=O)C=1C(C)=C(C=C2C3=CC(F)=CC=C3NC2=O)NC=1C)N1CCOCC1 CTNPALGJUAXMMC-MRXNPFEDSA-N 0.000 claims 1
- WINHZLLDWRZWRT-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(C=C2C3=CC(F)=CC=C3NC2=O)=C1C WINHZLLDWRZWRT-UHFFFAOYSA-N 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical group [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 claims 1
- LIZNIAKSBJKPQC-UHFFFAOYSA-N n-[2-(ethylamino)ethyl]-5-[(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound CCNCCNC(=O)C1=C(C)NC(C=C2C3=CC(F)=CC=C3NC2=O)=C1C LIZNIAKSBJKPQC-UHFFFAOYSA-N 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 229940063683 taxotere Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42638602P | 2002-11-15 | 2002-11-15 | |
| PCT/US2003/036526 WO2004045523A2 (en) | 2002-11-15 | 2003-11-14 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006508981A JP2006508981A (ja) | 2006-03-16 |
| JP2006508981A5 true JP2006508981A5 (enExample) | 2006-10-12 |
Family
ID=32326343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004553729A Withdrawn JP2006508981A (ja) | 2002-11-15 | 2003-11-14 | 癌を治療するためのインドリノンと化学療法剤との組み合わせ投与 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20040152759A1 (enExample) |
| EP (1) | EP1562600A4 (enExample) |
| JP (1) | JP2006508981A (enExample) |
| KR (1) | KR20050086594A (enExample) |
| CN (2) | CN100430060C (enExample) |
| AR (1) | AR042042A1 (enExample) |
| AU (1) | AU2003290943A1 (enExample) |
| BR (1) | BR0315630A (enExample) |
| CA (1) | CA2506308A1 (enExample) |
| CO (1) | CO5700778A2 (enExample) |
| GT (1) | GT200300245A (enExample) |
| MX (1) | MXPA05005150A (enExample) |
| NL (1) | NL1024779C2 (enExample) |
| NO (1) | NO20052578L (enExample) |
| PA (1) | PA8588601A1 (enExample) |
| PE (1) | PE20040835A1 (enExample) |
| PL (1) | PL376954A1 (enExample) |
| RU (1) | RU2342140C2 (enExample) |
| TW (1) | TW200418837A (enExample) |
| UY (1) | UY28081A1 (enExample) |
| WO (1) | WO2004045523A2 (enExample) |
| ZA (1) | ZA200503841B (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| US8962655B2 (en) | 2007-01-29 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
| US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| US12508313B2 (en) | 2009-08-19 | 2025-12-30 | Eisai R&D Management Co., Ltd. | Quinoline derivative-containing pharmaceutical composition |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX242553B (es) | 2000-10-20 | 2006-12-06 | Eisai Co Ltd | Derivados aromaticos que contienen nitrogeno. |
| WO2004080462A1 (ja) | 2003-03-10 | 2004-09-23 | Eisai Co., Ltd. | c-Kitキナーゼ阻害剤 |
| US7683172B2 (en) | 2003-11-11 | 2010-03-23 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
| JP5371426B2 (ja) * | 2004-07-09 | 2013-12-18 | プロルックス ファーマシューティカルズ コープ． | ワートマニン類似体及び化学療法薬と組み合わせた同一物を使用する方法 |
| WO2006030826A1 (ja) * | 2004-09-17 | 2006-03-23 | Eisai R & D Management Co., Ltd. | 医薬組成物 |
| US20090117197A1 (en) * | 2005-03-21 | 2009-05-07 | Vicus Therapeutics Llc | Compositions and methods for ameliorating cachexia |
| WO2006101692A1 (en) * | 2005-03-23 | 2006-09-28 | Pfizer Products Inc. | Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer |
| AU2006245421A1 (en) * | 2005-05-12 | 2006-11-16 | Pfizer Inc. | Anticancer combination therapy using sunitinib malate |
| HRP20100265T1 (hr) * | 2005-06-03 | 2010-06-30 | Novartis Ag | Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti |
| EP1925941B1 (en) * | 2005-08-01 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
| EP2281901B1 (en) | 2005-08-02 | 2013-11-27 | Eisai R&D Management Co., Ltd. | Anti-tumour pharmaceutical composition with angiogenesis inhibitors |
| AU2006285673B2 (en) * | 2005-09-01 | 2010-12-02 | Eisai R&D Management Co., Ltd. | Method for preparation of pharmaceutical composition having improved disintegratability |
| JP5238504B2 (ja) * | 2005-09-15 | 2013-07-17 | カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ | イミダゾリル基で置換された新規なステロイド誘導体およびインダン−１−オン誘導体 |
| AU2006293620A1 (en) * | 2005-09-20 | 2007-03-29 | Pfizer Products Inc. | Dosage forms and methods of treatment using a tyrosine kinase inhibitor |
| KR101353763B1 (ko) | 2005-11-07 | 2014-01-21 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 ｃ―ｋｉｔ 키나아제 저해 물질의병용 |
| WO2007061130A1 (ja) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | 多発性骨髄腫に対する抗腫瘍剤 |
| AU2007252506C1 (en) * | 2006-05-18 | 2012-07-19 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| DE102006024834B4 (de) * | 2006-05-24 | 2010-07-01 | Schebo Biotech Ag | Neue Indol-Pyrrol-Derivate und deren Verwendungen |
| JPWO2008001956A1 (ja) * | 2006-06-29 | 2009-12-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肝線維症治療剤 |
| CN1899616A (zh) * | 2006-07-20 | 2007-01-24 | 中国人民解放军军事医学科学院生物工程研究所 | 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途 |
| EP2065372B1 (en) | 2006-08-28 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| AU2008325608B2 (en) | 2007-11-09 | 2013-03-14 | Eisai R & D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| EP2242493B1 (en) * | 2008-01-22 | 2013-06-05 | Concert Pharmaceuticals Inc. | Derivatives of gefitinib |
| BRPI0906576A2 (pt) * | 2008-01-29 | 2015-07-07 | Eisai R&D Man Co Ltd | Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer |
| CN102137842A (zh) * | 2008-07-02 | 2011-07-27 | 基因里克斯(英国)有限公司 | 3-吡咯取代的2-吲哚酮衍生物的制备 |
| US20100143295A1 (en) * | 2008-12-05 | 2010-06-10 | Auspex Pharmaceuticals, Inc. | Quinazoline inhibitors of egfr tyrosine kinase |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| CN103127096B (zh) * | 2011-12-02 | 2015-11-25 | 杨子娇 | 吡咯基取代的吲哚类化合物在治疗青光眼病的应用 |
| US9931313B2 (en) * | 2012-04-04 | 2018-04-03 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating proliferative disorders with malate or derivatives thereof |
| CA2889866A1 (en) | 2012-12-21 | 2014-06-26 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| NZ714049A (en) | 2013-05-14 | 2020-05-29 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| HRP20221047T1 (hr) | 2014-08-28 | 2022-11-11 | Eisai R&D Management Co., Ltd. | Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju |
| HUE064614T2 (hu) | 2015-02-25 | 2024-04-28 | Eisai R&D Man Co Ltd | Eljárás egy kinolin-származék keserû ízének elnyomására |
| CA2978226C (en) | 2015-03-04 | 2025-02-18 | Eisai R&D Management Co., Ltd. | COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER |
| BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
| MX381976B (es) | 2015-08-20 | 2025-03-13 | Eisai R&D Man Co Ltd | Agente terapéutico contra tumores. |
| EP3470394B1 (en) * | 2016-06-09 | 2022-01-26 | Yuki Gosei Kogyo Co., Ltd. | Method for preparing 4-(piperidin-4-yl)morpholine |
| KR102539920B1 (ko) | 2017-02-08 | 2023-06-05 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 종양-치료용 약제학적 조성물 |
| RU2019134940A (ru) | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Лечение гепатоцеллюлярной карциномы |
| JP2022549680A (ja) * | 2019-09-26 | 2022-11-28 | スターファーマ ピーティーワイ エルティーディー | 治療用デンドリマー |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ283965B6 (cs) * | 1992-08-06 | 1998-07-15 | Warner-Lambert Company | 2-thioindolové, 2-indolinthionové a polysulfidové sloučeniny, 2-selenoindolové, 2-indolinselenonové a selenidové sloučeniny a farmaceutické prostředky na jejich bázi |
| DK2020408T3 (da) * | 1998-05-29 | 2013-09-30 | Sugen Inc | Pyrrol-substitueret 2-indolinon som proteinkinaseinhibitor |
| ATE514676T1 (de) * | 1999-11-24 | 2011-07-15 | Sugen Inc | Ionisierbare indolinon derivate und deren verwendung als ptk liganden |
| NZ519697A (en) * | 1999-12-22 | 2004-08-27 | Sugen Inc | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
| PT1255752E (pt) * | 2000-02-15 | 2007-10-17 | Pharmacia & Upjohn Co Llc | Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo |
| MY128450A (en) * | 2000-05-24 | 2007-02-28 | Upjohn Co | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| US6797725B2 (en) * | 2001-04-09 | 2004-09-28 | Sugen, Inc. | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
-
2003
- 2003-11-13 AR ARP030104194A patent/AR042042A1/es unknown
- 2003-11-14 KR KR1020057008541A patent/KR20050086594A/ko not_active Ceased
- 2003-11-14 RU RU2005118417/14A patent/RU2342140C2/ru not_active IP Right Cessation
- 2003-11-14 MX MXPA05005150A patent/MXPA05005150A/es unknown
- 2003-11-14 TW TW092132030A patent/TW200418837A/zh unknown
- 2003-11-14 NL NL1024779A patent/NL1024779C2/nl not_active IP Right Cessation
- 2003-11-14 EP EP03783527A patent/EP1562600A4/en not_active Withdrawn
- 2003-11-14 PA PA20038588601A patent/PA8588601A1/es unknown
- 2003-11-14 GT GT200300245A patent/GT200300245A/es unknown
- 2003-11-14 CA CA002506308A patent/CA2506308A1/en not_active Abandoned
- 2003-11-14 JP JP2004553729A patent/JP2006508981A/ja not_active Withdrawn
- 2003-11-14 WO PCT/US2003/036526 patent/WO2004045523A2/en not_active Ceased
- 2003-11-14 PE PE2003001154A patent/PE20040835A1/es not_active Application Discontinuation
- 2003-11-14 UY UY28081A patent/UY28081A1/es not_active Application Discontinuation
- 2003-11-14 CN CNB200380103225XA patent/CN100430060C/zh not_active Expired - Fee Related
- 2003-11-14 PL PL376954A patent/PL376954A1/pl not_active Application Discontinuation
- 2003-11-14 CN CNA2008100814220A patent/CN101259131A/zh active Pending
- 2003-11-14 AU AU2003290943A patent/AU2003290943A1/en not_active Abandoned
- 2003-11-14 BR BR0315630-3A patent/BR0315630A/pt not_active IP Right Cessation
- 2003-11-14 US US10/712,296 patent/US20040152759A1/en not_active Abandoned
-
2005
- 2005-05-11 CO CO05045078A patent/CO5700778A2/es not_active Application Discontinuation
- 2005-05-12 ZA ZA200503841A patent/ZA200503841B/en unknown
- 2005-05-27 NO NO20052578A patent/NO20052578L/no not_active Application Discontinuation
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8962655B2 (en) | 2007-01-29 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
| US12508313B2 (en) | 2009-08-19 | 2025-12-30 | Eisai R&D Management Co., Ltd. | Quinoline derivative-containing pharmaceutical composition |
| US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006508981A5 (enExample) | ||
| RU2005118417A (ru) | Комбинированное введение индолинона с химиотерапевтическим средством при нарушениях, вызванных клеточной пролиферацией | |
| JP7015059B2 (ja) | 置換複素環式基を含む２－置換キナゾリン化合物およびその使用方法 | |
| AU2016245864C1 (en) | Substituted quinazoline compounds and methods of use thereof | |
| AU2015369983B2 (en) | Thieno[2,3-c]pyrrol-4-one derivatives as ERK inhibitors | |
| AU2015280138B2 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| EP3867251A1 (en) | Kras g12c inhibitors | |
| JP2006521377A5 (enExample) | ||
| CA2997039C (en) | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | |
| RU2011103454A (ru) | Бициклические гетероциклы в качестве ингибиторов киназы мек | |
| SI2797918T1 (en) | Bromodomain inhibitors | |
| JP2014533299A5 (enExample) | ||
| HRP20151410T1 (hr) | Derivati pikolinamida kao inhibitori kinaze | |
| MX2009004715A (es) | Compuestos heterociclicos como agentes antiinflamatorios. | |
| RU2007110934A (ru) | Гетероциклические соединения и их применение | |
| JP2019529484A (ja) | Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤 | |
| JP2011515397A5 (enExample) | ||
| CA2651363A1 (en) | Triazolopyrazine derivatives useful as anti-cancer agents | |
| JP2020517616A5 (enExample) | ||
| JP2008535902A5 (enExample) | ||
| JP2017532360A5 (enExample) | ||
| JP2010540458A5 (enExample) | ||
| JP2017533266A5 (enExample) | ||
| CA2720944A1 (en) | Compounds and compositions as kinase inhibitors | |
| JP2013544799A5 (enExample) |